0	8	Possible	possible	JJ
9	20	differences	difference	NNS
21	23	in	in	IN
24	27	the	the	DT
28	40	mechanism(s)	mechanism(s)	NN
41	43	of	of	IN
44	50	action	action	NN
51	53	of	of	IN
54	63	different	different	JJ
64	78	glucocorticoid	glucocorticoid	NN
79	86	hormone	hormone	NN
87	96	compounds	compound	NNS
96	97	.	.	.

99	108	Different	different	JJ
109	123	glucocorticoid	glucocorticoid	NN
124	132	hormones	hormone	NNS
133	134	(	(	(
134	137	GCH	GCH	NNP
137	138	)	)	)
139	143	show	show	VBP
144	155	differences	difference	NNS
156	158	in	in	IN
159	162	the	the	DT
163	172	intensity	intensity	NN
173	176	and	and	CC
177	179	in	in	IN
180	183	the	the	DT
184	192	kinetics	kinetic	NNS
193	195	of	of	IN
196	201	their	their	PRP$
202	218	immunomodulating	immunomodulating	JJ
219	227	activity	activity	NN
227	228	.	.	.

229	232	The	the	DT
233	245	mechanism(s)	mechanism(s)	NN
246	248	of	of	IN
249	255	action	action	NN
256	258	of	of	IN
259	262	GCH	GCH	NNP
263	265	is	be	VBZ
266	271	under	under	IN
272	285	investigation	investigation	NN
285	286	,	,	,
287	290	but	but	CC
291	293	is	be	VBZ
294	297	has	have	VBZ
298	302	been	be	VBN
303	308	noted	note	VBN
309	313	that	that	IN
314	318	they	they	PRP
319	324	exert	exert	VBP
325	331	immune	immune	JJ
332	340	activity	activity	NN
341	344	via	via	IN
345	348	the	the	DT
349	356	genomic	genomic	JJ
357	364	pathway	pathway	NN
364	365	.	.	.

366	368	We	we	PRP
369	373	have	have	VBP
374	381	studied	study	VBN
382	385	the	the	DT
386	393	effects	effect	NNS
394	396	of	of	IN
397	407	prednisone	prednisone	NN
408	409	(	(	(
409	412	PDN	PDN	NNP
412	413	)	)	)
413	414	,	,	,
415	426	deflazacort	deflazacort	NN
427	428	(	(	(
428	431	DFC	DFC	NNP
431	432	)	)	)
432	433	,	,	,
434	437	and	and	CC
438	451	dexamethasone	dexamethasone	NN
452	453	(	(	(
453	456	DXM	DXM	NNP
456	457	)	)	)
458	460	on	on	IN
461	464	the	the	DT
465	475	production	production	NN
476	478	of	of	IN
479	488	cytokines	cytokine	NNS
489	490	(	(	(
490	494	IL-2	IL-2	NNP
494	495	,	,	,
496	500	IL-6	IL-6	NNP
500	501	,	,	,
502	511	TNF-alpha	TNF-alpha	NNP
511	512	,	,	,
513	518	IL-10	IL-10	NNP
518	519	)	)	)
520	522	by	by	IN
523	533	peripheral	peripheral	JJ
534	535	T	t	NN
536	547	lymphocytes	lymphocyte	NNS
547	548	,	,	,
549	552	and	and	CC
553	556	the	the	DT
557	564	effects	effect	NNS
565	567	on	on	IN
568	571	the	the	DT
572	582	inhibition	inhibition	NN
583	585	of	of	IN
586	591	NF-kB	NF-kB	NNP
592	595	DNA	DNA	NNP
596	603	binding	binding	NN
604	612	activity	activity	NN
613	615	by	by	IN
616	625	activated	activate	VBN
626	632	Jurkat	Jurkat	NNP
633	637	cell	cell	NN
638	642	line	line	NN
642	643	.	.	.

644	647	The	the	DT
648	652	data	datum	NNS
653	661	obtained	obtain	VBN
662	666	show	show	VBP
667	671	that	that	IN
672	675	the	the	DT
676	681	three	three	CD
682	685	GCH	GCH	NNP
686	695	molecules	molecule	NNS
696	701	exert	exert	VBP
702	704	an	an	DT
705	722	immunosuppression	immunosuppression	NN
723	725	on	on	IN
726	734	cytokine	cytokine	NN
735	745	production	production	NN
746	748	by	by	IN
749	750	T	t	NN
751	762	lymphocytes	lymphocyte	NNS
763	766	and	and	CC
767	768	a	a	DT
769	775	strong	strong	JJ
776	784	decrease	decrease	NN
785	787	in	in	IN
788	791	the	the	DT
792	799	nuclear	nuclear	JJ
800	813	translocation	translocation	NN
814	816	of	of	IN
817	822	NF-kB	NF-kB	NNP
823	825	in	in	IN
826	832	Jurkat	Jurkat	NNP
833	838	cells	cell	NNS
838	839	;	;	:
840	848	moreover	moreover	RB
848	849	,	,	,
850	851	(	(	(
851	852	a	a	DT
852	853	)	)	)
854	857	not	not	RB
858	861	all	all	PDT
862	865	the	the	DT
866	875	cytokines	cytokine	NNS
876	888	investigated	investigate	VBN
889	893	were	be	VBD
894	902	affected	affect	VBN
902	903	,	,	,
904	907	and	and	CC
908	911	not	not	RB
912	916	with	with	IN
917	920	the	the	DT
921	925	same	same	JJ
926	935	intensity	intensity	NN
935	936	,	,	,
937	939	by	by	IN
940	943	the	the	DT
944	949	three	three	CD
950	953	GCH	GCH	NNP
954	957	and	and	CC
958	959	(	(	(
959	960	b	b	LS
960	961	)	)	)
962	965	DXM	DXM	NNP
966	975	inhibited	inhibit	VBD
976	979	the	the	DT
980	987	binding	binding	NN
988	996	activity	activity	NN
997	999	of	of	IN
1000	1005	NF-kB	NF-kB	NNP
1006	1010	less	less	JJR
1011	1015	than	than	IN
1016	1020	that	that	DT
1021	1023	of	of	IN
1024	1027	DFC	DFC	NNP
1028	1031	and	and	CC
1032	1035	PDN	PDN	NNP
1035	1036	.	.	.

1037	1042	These	these	DT
1043	1047	data	datum	NNS
1048	1051	are	be	VBP
1052	1054	in	in	IN
1055	1064	agreement	agreement	NN
1065	1069	with	with	IN
1070	1073	the	the	DT
1074	1081	concept	concept	NN
1082	1086	that	that	IN
1087	1096	different	different	JJ
1097	1100	GCH	GCH	NNP
1101	1110	compounds	compound	NNS
1111	1116	might	might	MD
1117	1123	differ	differ	VB
1124	1126	in	in	IN
1127	1132	their	their	PRP$
1133	1140	binding	binding	NN
1141	1144	and	and	CC
1145	1153	affinity	affinity	NN
1154	1164	properties	property	NNS
1164	1165	,	,	,
1166	1181	tissue-specific	tissue-specific	JJ
1182	1192	metabolism	metabolism	NN
1192	1193	,	,	,
1194	1197	and	and	CC
1198	1209	interaction	interaction	NN
1210	1214	with	with	IN
1215	1228	transcription	transcription	NN
1229	1235	factor	factor	NN
1235	1236	.	.	.